Smoking Cessation Program: A Quality Improvement Trial in a Resident-Based Outpatient Clinic

This study has been terminated.
Sponsor:
Information provided by:
Atlantic Health System
ClinicalTrials.gov Identifier:
NCT00436943
First received: February 16, 2007
Last updated: July 9, 2010
Last verified: July 2010
  Purpose

The researchers hypothesize that smoking cessation counseling improves with the implementation of a smoking status assessment data sheet in routine consults. This is a quality improvement study design to evaluate the impact of the implementation of a more formal smoking status evaluation in a resident/faculty driven outpatient clinic.


Condition Intervention
Smoking
Drug: nicotine replacement therapy and bupropion
Behavioral: smoking cessation counseling and referrals

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Smoking Cessation Program: A Quality Improvement Trial in a Resident Based Outpatient Clinic

Resource links provided by NLM:


Further study details as provided by Atlantic Health System:

Estimated Enrollment: 900
Study Start Date: January 2007
Estimated Study Completion Date: January 2008
Groups/Cohorts Assigned Interventions
A
Smokers
Drug: nicotine replacement therapy and bupropion
3-6 months
Behavioral: smoking cessation counseling and referrals
Organizational counseling and referrals

Detailed Description:

We hypothesize that smoking cessation counseling improves with the implementation of a smoking status assessment data sheet in routine consults. This is a quality improvement study design to evaluate the impact of the implementation of a more formal smoking status evaluation in a resident/faculty driven outpatient clinic. This will be an observational study in which differences in quality measures will be compared between baseline and re-measurement periods. Population target: 900 patients screened before and after the implementation of the QI intervention. Primary outcome: smoking status evaluation. Secondary Outcome: number of patients advised to quit, plan implementation for smoking cessation, smoking cessation program referrals, number of NRT and bupropion prescription.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Outpatient clinic

Criteria

Inclusion Criteria:

  • 21 years or older
  • Seen at MMH family health center
  • Current smoker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00436943

Locations
United States, New Jersey
Family Health Center at Morristown Memorial Hospital
Morristown, New Jersey, United States, 07960
Sponsors and Collaborators
Atlantic Health System
Investigators
Principal Investigator: Patricia Harris, MD Atlantic Health System - Morristown Memorial Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00436943     History of Changes
Other Study ID Numbers: R06-12-021, Smoking Cessation
Study First Received: February 16, 2007
Last Updated: July 9, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Atlantic Health System:
smoking cessation
nicotine replacement therapy
bupropion
smoking

Additional relevant MeSH terms:
Nicotine
Bupropion
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on September 16, 2014